2016 Q1 Form 10-Q Financial Statement
#000114420416100536 Filed on May 10, 2016
Income Statement
| Concept | 2016 Q1 | 2015 Q4 | 2015 Q1 |
|---|---|---|---|
| Revenue | $660.0K | $338.0K | $500.0K |
| YoY Change | 32.0% | ||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $7.930M | $7.210M | $3.490M |
| YoY Change | 127.22% | 125.31% | 66.19% |
| % of Gross Profit | |||
| Research & Development | $7.736M | $5.760M | $1.642M |
| YoY Change | 371.13% | 225.42% | -63.41% |
| % of Gross Profit | |||
| Depreciation & Amortization | $4.000K | $10.00K | $6.000K |
| YoY Change | -33.33% | 20.0% | |
| % of Gross Profit | |||
| Operating Expenses | $15.75M | $12.96M | $12.57M |
| YoY Change | 25.3% | 161.29% | 90.99% |
| Operating Profit | -$15.57M | -$12.96M | -$12.57M |
| YoY Change | 23.86% | 161.32% | 90.99% |
| Interest Expense | $620.0K | -$2.450M | $331.0K |
| YoY Change | 87.31% | -296.0% | -65.73% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$1.552M | -$464.0K | |
| YoY Change | 234.48% | -41.12% | |
| Pretax Income | -$16.64M | -$15.08M | -$12.54M |
| YoY Change | 32.7% | 306.47% | 70.15% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$12.21M | -$12.04M | -$12.06M |
| YoY Change | 1.24% | 224.16% | 63.58% |
| Net Earnings / Revenue | -1849.24% | -3560.95% | -2411.2% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$307.9K | -$305.0K | -$312.7K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 47.13M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2016 Q1 | 2015 Q4 | 2015 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $81.40M | $98.20M | $72.88M |
| YoY Change | 11.69% | 32.84% | -8.9% |
| Cash & Equivalents | $81.42M | $98.18M | $48.93M |
| Short-Term Investments | $23.95M | ||
| Other Short-Term Assets | $1.600M | $1.600M | $700.0K |
| YoY Change | 128.57% | 128.57% | 40.0% |
| Inventory | $0.00 | ||
| Prepaid Expenses | |||
| Receivables | $0.00 | ||
| Other Receivables | $200.0K | ||
| Total Short-Term Assets | $84.30M | $99.94M | $69.60M |
| YoY Change | 21.12% | 41.83% | -13.54% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.600M | $309.0K | $0.00 |
| YoY Change | 494.23% | -100.0% | |
| Goodwill | $0.00 | ||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $250.0K | $250.0K | $250.0K |
| YoY Change | 0.0% | 0.0% | 0.0% |
| Other Assets | $15.00M | $43.00K | $15.60M |
| YoY Change | -3.85% | -32.81% | 22185.71% |
| Total Long-Term Assets | $20.60M | $18.67M | $20.90M |
| YoY Change | -1.44% | -1.0% | 45.16% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $84.30M | $99.94M | $69.60M |
| Total Long-Term Assets | $20.60M | $18.67M | $20.90M |
| Total Assets | $104.9M | $118.6M | $90.50M |
| YoY Change | 15.91% | 32.78% | -4.64% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.300M | $1.868M | $700.0K |
| YoY Change | 228.57% | 410.38% | -19.72% |
| Accrued Expenses | $7.800M | $8.570M | $5.300M |
| YoY Change | 47.17% | 132.69% | 54.16% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $10.80M | $10.58M | $5.900M |
| YoY Change | 83.05% | 159.48% | 36.1% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $20.80M | $23.20M | $24.00M |
| YoY Change | -13.33% | 65.71% | 71.43% |
| Other Long-Term Liabilities | $2.400M | $584.0K | $300.0K |
| YoY Change | 700.0% | -19.11% | -71.86% |
| Total Long-Term Liabilities | $23.20M | $584.0K | $24.30M |
| YoY Change | -4.53% | -19.11% | 2179.55% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $10.80M | $10.58M | $5.900M |
| Total Long-Term Liabilities | $23.20M | $584.0K | $24.30M |
| Total Liabilities | $60.30M | $34.34M | $30.30M |
| YoY Change | 99.01% | 82.62% | 56.11% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$190.2M | ||
| YoY Change | 34.17% | ||
| Common Stock | $47.00K | ||
| YoY Change | 2.17% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $44.57M | $56.85M | $60.20M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $104.9M | $118.6M | $90.50M |
| YoY Change | 15.91% | 32.78% | -4.64% |
Cashflow Statement
| Concept | 2016 Q1 | 2015 Q4 | 2015 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$12.21M | -$12.04M | -$12.06M |
| YoY Change | 1.24% | 224.16% | 63.58% |
| Depreciation, Depletion And Amortization | $4.000K | $10.00K | $6.000K |
| YoY Change | -33.33% | 20.0% | |
| Cash From Operating Activities | -$11.64M | $2.860M | -$1.910M |
| YoY Change | 509.42% | -181.25% | -68.53% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $2.293M | -$190.0K | $0.00 |
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$210.0K | $29.49M | -$7.040M |
| YoY Change | -97.02% | -230.08% | 2716.0% |
| Cash From Investing Activities | -$2.700M | $29.30M | -$8.290M |
| YoY Change | -67.43% | -229.25% | 3216.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | ||
| YoY Change | -100.0% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -2.430M | 40.46M | 9.360M |
| YoY Change | -125.96% | 825.86% | -170.8% |
| NET CHANGE | |||
| Cash From Operating Activities | -11.64M | 2.860M | -1.910M |
| Cash From Investing Activities | -2.700M | 29.30M | -8.290M |
| Cash From Financing Activities | -2.430M | 40.46M | 9.360M |
| Net Change In Cash | -16.77M | 72.62M | -840.0K |
| YoY Change | 1896.43% | -432.81% | -95.7% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$11.64M | $2.860M | -$1.910M |
| Capital Expenditures | $2.293M | -$190.0K | $0.00 |
| Free Cash Flow | -$13.93M | $3.050M | -$1.910M |
| YoY Change | 629.48% | -186.65% | -68.53% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2015Q1 | fbio |
Payment For Research And Development Licenses
PaymentForResearchAndDevelopmentLicenses
|
6929000 | USD |
| CY2016Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
14600000 | USD |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
56846000 | USD |
| CY2015Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
84273000 | USD |
| CY2016Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
14586000 | USD |
| CY2015Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
14586000 | USD |
| CY2016Q1 | us-gaap |
Long Term Investments
LongTermInvestments
|
1567000 | USD |
| CY2015Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
2485000 | USD |
| CY2016Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
44565000 | USD |
| CY2016Q1 | us-gaap |
Minority Interest
MinorityInterest
|
26344000 | USD |
| CY2015Q4 | us-gaap |
Minority Interest
MinorityInterest
|
27427000 | USD |
| CY2016Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
70909000 | USD |
| CY2016Q1 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
203000 | USD |
| CY2015Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
114000 | USD |
| CY2016Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2016Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
277000 | USD |
| CY2015Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
500000 | USD |
| CY2016Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
660000 | USD |
| CY2015Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
500000 | USD |
| CY2016Q1 | us-gaap |
Sales Revenue Services Net
SalesRevenueServicesNet
|
383000 | USD |
| CY2015Q1 | us-gaap |
Sales Revenue Services Net
SalesRevenueServicesNet
|
0 | USD |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7736000 | USD |
| CY2015Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1642000 | USD |
| CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7932000 | USD |
| CY2015Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3490000 | USD |
| CY2015Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
12571000 | USD |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-15091000 | USD |
| CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12071000 | USD |
| CY2016Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
75000 | USD |
| CY2015Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
82000 | USD |
| CY2016Q1 | fbio |
Accretion And Interest Expenses
AccretionAndInterestExpenses
|
620000 | USD |
| CY2015Q1 | fbio |
Accretion And Interest Expenses
AccretionAndInterestExpenses
|
331000 | USD |
| CY2016Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
89000 | USD |
| CY2015Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | USD |
| CY2016Q1 | fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-918000 | USD |
| CY2015Q1 | fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-215000 | USD |
| CY2016Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1552000 | USD |
| CY2015Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-464000 | USD |
| CY2016Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-16643000 | USD |
| CY2015Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-12535000 | USD |
| CY2016Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-4438000 | USD |
| CY2015Q1 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-479000 | USD |
| CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12056000 | USD |
| CY2015Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.31 | |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
38574702 | shares |
| CY2016Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
4000 | USD |
| CY2015Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
6000 | USD |
| CY2016Q1 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
0 | USD |
| CY2015Q1 | us-gaap |
Other Noncash Expense
OtherNoncashExpense
|
188000 | USD |
| CY2016Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
369000 | USD |
| CY2015Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
0 | USD |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2866000 | USD |
| CY2015Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1470000 | USD |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
1832000 | USD |
| CY2015Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-500000 | USD |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-11637000 | USD |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1905000 | USD |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2293000 | USD |
| CY2015Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | USD |
| CY2016Q1 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
2792000 | USD |
| CY2015Q1 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
0 | USD |
| CY2016Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD |
| CY2015Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
216000 | USD |
| CY2016Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
570000 | USD |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
0 | USD |
| CY2016Q1 | us-gaap |
Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
|
205000 | USD |
| CY2015Q1 | us-gaap |
Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
|
0 | USD |
| CY2016Q1 | us-gaap |
Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
|
0 | USD |
| CY2015Q1 | us-gaap |
Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
|
10000000 | USD |
| CY2016Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
0 | USD |
| CY2015Q1 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
855000 | USD |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
48928000 | USD |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
49759000 | USD |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-16767000 | USD |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-831000 | USD |
| CY2016Q1 | us-gaap |
Interest Paid
InterestPaid
|
77000 | USD |
| CY2015Q1 | us-gaap |
Interest Paid
InterestPaid
|
80000 | USD |
| CY2016Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
2000 | USD |
| CY2015Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
1000 | USD |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-2427000 | USD |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
9361000 | USD |
| CY2016Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
200000 | USD |
| CY2015Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
1250000 | USD |
| CY2016Q1 | fbio |
Issuance Of Common Stock For License Expenses
IssuanceOfCommonStockForLicenseExpenses
|
-48000 | USD |
| CY2015Q1 | fbio |
Issuance Of Common Stock For License Expenses
IssuanceOfCommonStockForLicenseExpenses
|
-513000 | USD |
| CY2016Q1 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
175000 | USD |
| CY2015Q1 | us-gaap |
Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
|
108000 | USD |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-2703000 | USD |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-8287000 | USD |
| CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
166000 | USD |
| CY2015Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-22000 | USD |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
169000 | USD |
| CY2015Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
1853000 | USD |
| CY2016Q1 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
0 | USD |
| CY2015Q1 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
-2000 | USD |
| CY2016Q1 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
35000 | USD |
| CY2015Q1 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
6929000 | USD |
| CY2016Q1 | fbio |
Payment For Research And Development Licenses
PaymentForResearchAndDevelopmentLicenses
|
35000 | USD |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
377000 | USD |
| CY2016Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
60000 | USD |
| CY2016Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2658000 | USD |
| CY2015Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
68000 | USD |
| CY2016Q1 | us-gaap |
Depreciation
Depreciation
|
4000 | USD |
| CY2015Q1 | us-gaap |
Depreciation
Depreciation
|
6000 | USD |
| CY2014Q1 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
250000 | USD |
| CY2014Q1 | us-gaap |
Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
|
0.35 | pure |
| CY2016Q1 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
250000 | USD |
| CY2016Q1 | fbio |
Percentage Of Outstanding Stock To Be Issued Upon Exercise Of Warrants
PercentageOfOutstandingStockToBeIssuedUponExerciseOfWarrants
|
0.25 | pure |
| CY2016Q1 | us-gaap |
Equity Method Investments Fair Value Disclosure
EquityMethodInvestmentsFairValueDisclosure
|
1567000 | USD |
| CY2015Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
2485000 | USD |
| CY2016Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
1567000 | USD |
| CY2016Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
|
-918000 | USD |
| CY2015Q1 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
1470000 | USD |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1779365 | shares |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | shares |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1779365 | shares |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
1082168 | shares |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.37 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
666396 | USD |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
853984 | USD |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.37 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
3.75 | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P6Y3M25D | |
| CY2016Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P6Y25D | |
| CY2016Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P5Y7M13D | |
| CY2016Q1 | fbio |
Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue
|
0 | USD |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
805651 | USD |
| CY2015Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1500000 | shares |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
11131304 | shares |
| CY2015Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10489695 | shares |
| CY2016Q1 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
762000 | USD |
| CY2015Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
2492000 | USD |
| CY2016Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
749000 | USD |
| CY2015Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
382000 | USD |
| CY2016Q1 | fbio |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
746000 | USD |
| CY2015Q4 | fbio |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
810000 | USD |
| CY2016Q1 | fbio |
Other Short Term Liabilities Related To Manufacturing Rights
OtherShortTermLiabilitiesRelatedToManufacturingRights
|
1500000 | USD |
| CY2015Q4 | fbio |
Other Short Term Liabilities Related To Manufacturing Rights
OtherShortTermLiabilitiesRelatedToManufacturingRights
|
1500000 | USD |
| CY2016Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
521000 | USD |
| CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
523000 | USD |
| CY2016Q1 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
2399000 | USD |
| CY2015Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
493000 | USD |
| CY2016Q1 | fbio |
Accrued Expenses Releted To Dr Falk Pharma Milestone
AccruedExpensesReletedToDrFalkPharmaMilestone
|
2828000 | USD |
| CY2016Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
21217000 | USD |
| CY2015Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
24009000 | USD |
| CY2015Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
835000 | USD |
| CY2016Q1 | us-gaap |
Interest Expense
InterestExpense
|
620000 | USD |
| CY2015Q1 | us-gaap |
Interest Expense
InterestExpense
|
331000 | USD |
| CY2015Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2016Q1 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
446000 | USD |
| CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q1 | us-gaap |
Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
|
0.1025 | pure |
| CY2016Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2016Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2016Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
48517449 | shares |
| CY2016Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
48517449 | shares |
| CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
47147032 | shares |
| CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
47147032 | shares |
| CY2016Q1 | us-gaap |
Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
|
0 | USD |
| CY2015Q1 | us-gaap |
Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
|
2000 | USD |
| CY2016Q1 | us-gaap |
Trading Securities Realized Gain Loss
TradingSecuritiesRealizedGainLoss
|
0 | USD |
| CY2015Q1 | us-gaap |
Trading Securities Realized Gain Loss
TradingSecuritiesRealizedGainLoss
|
1000 | USD |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
0 | USD |
| CY2015Q1 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
61000 | USD |
| CY2016Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016Q1 | us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
30782000 | USD |
| CY2015 | us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
32882000 | USD |
| CY2015 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-5455000 | USD |
| CY2015Q4 | fbio |
Accrued Expenses Releted To Dr Falk Pharma Milestone
AccruedExpensesReletedToDrFalkPharmaMilestone
|
2717000 | USD |
| CY2016Q1 | us-gaap |
Customer Deposits Current
CustomerDepositsCurrent
|
1007000 | USD |
| CY2016Q1 | fbio |
Percentage Of Tax Benefit Likely Of Being Realized
PercentageOfTaxBenefitLikelyOfBeingRealized
|
0.5 | pure |
| CY2016Q1 | us-gaap |
Fair Value Assumptions Weighted Average Volatility Rate
FairValueAssumptionsWeightedAverageVolatilityRate
|
0.256 | pure |
| CY2016Q1 | us-gaap |
Investment Owned At Fair Value
InvestmentOwnedAtFairValue
|
1300000 | USD |
| CY2015Q4 | us-gaap |
Customer Deposits Current
CustomerDepositsCurrent
|
0 | USD |
| CY2016Q1 | us-gaap |
Costs And Expenses Related Party
CostsAndExpensesRelatedParty
|
63000 | USD |
| CY2015Q1 | us-gaap |
Costs And Expenses Related Party
CostsAndExpensesRelatedParty
|
40000 | USD |
| CY2016Q1 | us-gaap |
Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
|
P5Y | |
| CY2016Q1 | us-gaap |
Prepaid Rent
PrepaidRent
|
199000 | USD |
| CY2016Q1 | fbio |
Lease Sharing Agreements Contributions To Property Under Lease
LeaseSharingAgreementsContributionsToPropertyUnderLease
|
2300000 | USD |
| CY2015Q1 | fbio |
Agreement Description Terms
AgreementDescriptionTerms
|
(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of Checkpoint common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of Checkpoint common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when the Company no longer has majority voting control in Checkpoint’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of its annual net sales, payable on an annual basis, within 90 days of the end of each calendar year. In the event of a change in control (as defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five times (5x) the product of (i) monthly net sales for the 12 months immediately preceding the change in control and (ii) four and one half percent (4.5%) | |
| CY2015Q1 | fbio |
Agreement Description Terms
AgreementDescriptionTerms
|
(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to to two and one half percent (2.5%) of the fully-diluted outstanding equity of Avenue at the time of issuance; (ii) pay an equity fee in shares of Avenue common stock, payable within five (5) business days of the closing of any equity or debt financing for Avenue or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Avenue’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of our annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%). | |
| CY2016Q1 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
2800000 | USD |
| CY2016Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1100000 | USD |
| CY2016Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
62000 | USD |
| CY2016Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P1M6D | |
| CY2016Q1 | fbio |
Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage
EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage
|
0.85 | pure |
| CY2015Q1 | fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
9000 | USD |
| CY2016Q1 | fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
0 | USD |
| CY2015Q1 | fbio |
Agreement Description Terms
AgreementDescriptionTerms
|
(i) issue annually to the Company, on the anniversary date of the Founders Agreement, shares of common stock equal to to two and one half percent (2.5%) of the fully-diluted outstanding equity of Helocyte at the time of issuance; (ii) pay an equity fee in shares of Helocyte common stock, payable within five (5) business days of the closing of any equity or debt financing for Helocyte or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Helocyte’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of our annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) monthly net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%). | |
| CY2016Q1 | fbio |
Related Party Other Investment Percentage In Entity By Principal Stockholder Or Director
RelatedPartyOtherInvestmentPercentageInEntityByPrincipalStockholderOrDirector
|
0.154 | pure |
| CY2015Q4 | fbio |
Related Party Other Investment Percentage In Entity By Principal Stockholder Or Director
RelatedPartyOtherInvestmentPercentageInEntityByPrincipalStockholderOrDirector
|
0.148 | pure |
| CY2015Q4 | us-gaap |
Equity Method Investments Fair Value Disclosure
EquityMethodInvestmentsFairValueDisclosure
|
2485000 | USD |
| CY2015Q4 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
250000 | USD |
| CY2016Q1 | us-gaap |
Share Price
SharePrice
|
9.61 | |
| CY2016Q1 | us-gaap |
Sale Of Stock Percentage Of Ownership After Transaction
SaleOfStockPercentageOfOwnershipAfterTransaction
|
0.25 | pure |
| CY2016Q1 | us-gaap |
Investments In And Advances To Affiliates At Fair Value Period Increase Decrease
InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease
|
900000 | USD |
| CY2016Q1 | us-gaap |
Notes Payable
NotesPayable
|
14000000 | USD |
| CY2016Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
324000 | USD |
| CY2016Q1 | fbio |
Terms Of Clinical Reasearch Support Agreement
TermsOfClinicalReasearchSupportAgreement
|
Under the terms of the agreement an additional $1.0 million is due when certain clinical milestones are achieved using the initial $1.0 million. An additional $2.4 million is due upon the achievement of certain clinical and other milestones. The agreement expires upon the delivery of a final study report or May 31, 2018 unless terminated earlier. | |
| CY2016Q1 | us-gaap |
Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
|
1314000 | USD |
| CY2015Q4 | us-gaap |
Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
|
156000 | USD |
| CY2016Q1 | us-gaap |
Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
|
1158000 | USD |
| CY2015Q1 | us-gaap |
Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
|
0 | USD |
| CY2014Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
4160000 | USD |
| CY2015Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
|
-215000 | USD |
| CY2015Q1 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
3945000 | USD |
| CY2016Q1 | fbio |
Reimbursment Of Cost Recognised As Revenue
ReimbursmentOfCostRecognisedAsRevenue
|
300000 | USD |
| CY2016Q1 | fbio |
Reimbursment Of Cost Recognised As Revenue
ReimbursmentOfCostRecognisedAsRevenue
|
300000 | USD |
| CY2016Q1 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" align="left"><b>Reclassification</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" align="left"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" align="left">Certain reclassifications have been made to prior year amounts to conform to the current year presentation in the condensed consolidated statements of cash flows.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2016Q1 | fbio |
Accrued Lease Costs For Abondoned Properties Current
AccruedLeaseCostsForAbondonedPropertiesCurrent
|
146000 | USD |
| CY2015Q4 | fbio |
Accrued Lease Costs For Abondoned Properties Current
AccruedLeaseCostsForAbondonedPropertiesCurrent
|
146000 | USD |
| CY2016Q1 | fbio |
Accrued Lease Costs For Abondoned Properties Noncurrent
AccruedLeaseCostsForAbondonedPropertiesNoncurrent
|
17000 | USD |
| CY2015Q4 | fbio |
Accrued Lease Costs For Abondoned Properties Noncurrent
AccruedLeaseCostsForAbondonedPropertiesNoncurrent
|
91000 | USD |
| CY2016Q1 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
10000 | shares |
